## **Deloitte.**



### Symic OA ApS

Herlev Hovedgade 205 2730 Herlev CVR No. 40848460

### Annual report 2021

The Annual General Meeting adopted the annual report on 28.06.2022

**Thomas Nielsen** Chairman of the General Meeting

## Contents

Entity details	2
Statement by Management	3
Independent auditor's report	4
Management commentary	7
Income statement for 2021	8
Balance sheet at 31.12.2021	9
Statement of changes in equity for 2021	11
Notes	12
Accounting policies	14

## **Entity details**

### Entity

Symic OA ApS Herlev Hovedgade 205 2730 Herlev

Business Registration No.: 40848460 Date of foundation: 08.10.2019 Registered office: Herlev Financial year: 01.01.2021 - 31.12.2021

### **Executive Board**

Thomas Nielsen

### **Auditors**

Deloitte Statsautoriseret Revisionspartnerselskab Weidekampsgade 6 2300 Copenhagen S

## **Statement by Management**

The Executive Board has today considered and approved the annual report of Symic OA ApS for the financial year 01.01.2021 - 31.12.2021.

The annual report is presented in accordance with the Danish Financial Statements Act.

In my opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2021 and of the results of its operations for the financial year 01.01.2021 - 31.12.2021.

I believe that the management commentary contains a fair review of the affairs and conditions referred to therein.

I recommend the annual report for adoption at the Annual General Meeting.

Herlev, 28.06.2022

**Executive Board** 

**Thomas Nielsen** 

## Independent auditor's report

### To the shareholders of Symic OA ApS

### **Adverse opinion**

We have audited the financial statements of Symic OA ApS for the financial year 01.01.2021 - 31.12.2021, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, due to the significance of the matter discussed in the "Basis for adverse opinion" section, the financial statements do not give a true and fair view of the Entity's financial position at 31.12.2021 and of the results of its operations for the financial year 01.01.2021 - 31.12.2021 in accordance with the Danish Financial Statements Act.

### **Basis for adverse opinion**

Management has prepared the Annual Report under the assumption of going concern. The balance sheet shows net current liabilites of 299.8m DKK. The company has not provided us with documentation indicating that the Company has sufficient funds, or will be reveice additional financial funds form shareholders, in order to be able to pay the current liabilies once they are due.

Based on the above, there is considerable doubt about the going concern assumption for the company. Our conclusion is adverse regarding this assumption.

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of this auditor's report. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our adverse opinion.

### Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Entity's ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are

free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to
  fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence
  that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a
  material misstatement resulting from fraud is higher than for one resulting from error, as fraud may
  involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures in the notes, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

### Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with

the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.

Copenhagen, 28.06.2022

**Deloitte** Statsautoriseret Revisionspartnerselskab CVR No. 33963556

### Jan Larsen

State Authorised Public Accountant Identification No (MNE) mne16541

### **Management commentary**

### **Primary activities**

The object of the Company is to operate within development of pharmaceuticals and other related business.

### Profit/loss for the year in relation to expected developments

The Company received negative results of its main assets – an osteoarthritis drug late in 2021. As a consequence of this we have decided to abandon the intellectual property held be the Company and to write down all capitalized acquisition and development cost.

As a consequence of this the years result show a loss at (307,017,346) DKK. The Executive Board considers the operating result of the year as unsatisfied.

The Equity shows a negative value at (287,155,746) DKK.

### Events after the balance sheet date

No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.

## **Income statement for 2021**

		2021	2020
	Notes	DKK	DKK
Administrative expenses		(1,249,184)	(489,865)
Operating profit/loss		(1,249,184)	(489,865)
Income from financial assets		(297,088,502)	0
Other financial income	1	0	19,969,459
Other financial expenses	2	(8,679,660)	(22,243)
Profit/loss for the year		(307,017,346)	19,457,351
Proposed distribution of profit and loss			
Retained earnings		(307,017,346)	19,457,351
Proposed distribution of profit and loss		(307,017,346)	19,457,351

## Balance sheet at 31.12.2021

### Assets

		2021	2020
	Notes	DKK	DKK
Acquired patents		0	206,592,000
Development projects in progress	4	0	67,290,677
Intangible assets	3	0	273,882,677
Fixed assets		0	273,882,677
Other receivables		2,437,529	7,158,783
Prepayments		0	1,028,490
Receivables		2,437,529	8,187,273
Cash		10,226,021	3,655,640
Current assets		12,663,550	11,842,913
Assets		12,663,550	285,725,590

### **Equity and liabilities**

		2021	2020
	Notes	DKK	DKK
Contributed capital		404,248	404,248
Retained earnings		(287,559,994)	19,457,351
Equity		(287,155,746)	19,861,599
Subordinate loan capital		132,488,251	117,616,151
Non-current liabilities other than provisions	5	132,488,251	117,616,151
Trade payables		12,595,475	2,378,611
Payables to group enterprises		152,219,840	144,837,216
Other payables		2,515,730	1,032,013
Current liabilities other than provisions		167,331,045	148,247,840
Liabilities other than provisions		299,819,296	265,863,991
Equity and liabilities		12,663,550	285,725,590

# Statement of changes in equity for 2021

	Contributed capital DKK	Retained earnings DKK	Total DKK
Equity beginning of year	404,248	19,457,352	19,861,600
Profit/loss for the year	0	(307,017,346)	(307,017,346)
Equity end of year	404,248	(287,559,994)	(287,155,746)

## Notes

### **1 Other financial income**

	2021 DKK	2020 DKK
Exchange rate adjustments	0	19,969,459
	0	19,969,459

### 2 Other financial expenses

	2021 DKK	2020 DKK
Other interest expenses	40,359	20,073
Exchange rate adjustments	8,635,909	0
Other financial expenses	3,392	2,170
	8,679,660	22,243

### 3 Intangible assets

	۲ Acquired patents DKK	Development projects in progress
		DKK DKK
Cost beginning of year	206,592,000	67,290,677
Additions	0	23,205,825
Cost end of year	206,592,000	90,496,502
Impairment losses for the year	(206,592,000)	(90,496,502)
Amortisation and impairment losses end of year	(206,592,000)	(90,496,502)
Carrying amount end of year	0	0

### **4 Development projects**

Development projects in progress relate to medicine for osteoarthritis. The project was taken over from Symic OA Inc. in the autumn of 2019.

The project has been written down since the projects has failed in test. At this moment, there is no plans to contining this development of this project.

### 5 Non-current liabilities other than provisions

	Due after more than 12 months 2021 DKK
Subordinate loan capital	132,488,251
	132,488,251

## **Accounting policies**

### **Reporting class**

This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises with addition of a few provisions for reporting class C.

The accounting policies applied to these financial statements are consistent with those applied last year.

### **Recognition and measurement**

Assets are recognised in the balance sheet when it is probable as a result of a prior event that future economic benefits will flow to the Entity, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when the Entity has a legal or constructive obligation as a result of a prior event, and it is probable that future economic benefits will flow out of the Entity, and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.

Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and measurement.

Income is recognised in the income statement when earned, whereas costs are recognised by the amounts attributable to this financial year.

### **Foreign currency translation**

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are translated using the exchange rate at the balance sheet date. Exchange differences that arise between the rate at the transaction date and the rate in effect at the payment date, or the rate at the balance sheet date, are recognised in the income statement as financial income or financial expenses.

### **Income statement**

### Administrative expenses

Administrative expenses comprise expenses incurred for the Entity's administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies, and amortisation, depreciation and impairment losses relating to intangible assets and property, plant and equipment used for administration of the Entity.

### Income from other fixed asset investments

Income from other fixed asset investments comprises gains in the form of interest, dividends, etc on fixed asset investments which are not investments in group enterprises or associates.

#### Other financial income

Other financial income comprises dividends etc received on other investments, interest income, including

interest income on receivables from group enterprises, net capital or exchange gains on securities, payables and transactions in foreign currencies, amortisation of financial assets, and tax relief under the Danish Tax Prepayment Scheme etc.

### Other financial expenses

Other financial expenses comprise interest expenses, payables and transactions in foreign currencies, amortisation of financial liabilities, and tax surcharge under the Danish Tax Prepayment Scheme etc.

### **Balance sheet**

### Intellectual property rights etc

Intellectual property rights etc comprise development projects completed and in progress with related intellectual property rights, acquired intellectual property rights and prepayments for intangible assets.

Development projects on clearly defined and identifiable products and processes, for which the technical rate of utilisation, adequate resources and a potential future market or development opportunity in the enterprise can be established, and where the intention is to manufacture, market or apply the product or process in question, are recognised as intangible assets. Other development costs are recognised as costs in the income statement as incurred. When recognising development projects as intangible assets, an amount equalling the costs incurred less deferred tax is taken to equity under Reserve for development costs that is reduced as the development projects are amortised and written down.

The cost of development projects comprises costs such as salaries and amortisation that are directly and indirectly attributable to the development projects.

Completed development projects are amortised on a straight-line basis using their estimated useful lives which are determined based on a specific assessment of each development project. If the useful life cannot be estimated reliably, it is fixed at 10 years. For development projects protected by intellectual property rights, the maximum period of amortisation is the remaining duration of the relevant rights. The amortisation periods used are 10 years.

Intellectual property rights acquired are measured at cost less accumulated amortisation. Patents are amortised on a straight-line basis over their remaining duration, and licences are amortised over the term of the agreement.

Intellectual property rights etc are written down to the lower of recoverable amount and carrying amount.

### Receivables

Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.

### Prepayments

Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.

### Cash

Cash comprises cash in hand and bank deposits.

### **Other financial liabilities**

Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.